PMID- 25760219
OWN - NLM
STAT- MEDLINE
DCOM- 20151229
LR  - 20191113
IS  - 1875-5739 (Electronic)
IS  - 1567-2026 (Linking)
VI  - 12
IP  - 2
DP  - 2015
TI  - Etanercept improves cognitive performance and increases eNOS and BDNF expression 
      during experimental vascular dementia in streptozotocin-induced diabetes.
PG  - 135-46
AB  - Diabetes mellitus (DM) is related to an increase in the incidence of vascular 
      dementia. Inflammation is an important cause of endothelial dysfunction and 
      cognitive deficits. The anti -tumor necrosis factor (TNF)-alpha fusion protein 
      etanercept has been reported to exhibit memory-enhancing effects and endothelial 
      protection. We tested the effect of etanercept on the cognitive endpoints and 
      compared it with the cognitive dysfunction in streptozotocin (STZ )- induced DM 
      rats by using the Morris water maze test (MWMT) and passive avoidance test (PAT). 
      Systolic blood pressure (SBP), thoracic endothelial function, endothelial nitric 
      oxide synthase (eNOS) expression, and hippocampal brain-derived neurotrophic 
      factor (BDNF) expression were assessed. Thirty days after the induction of DM, 
      rats exhibited severe learning and memory deficits associated with endothelial 
      dysfunction and decreased expression of eNOS and BDNF. Chronic treatment with 
      etanercept (0.8 mg/kg, s.c., every week for 30 days) improved cognitive 
      performance, endothelial function, and expression of eNOS and BDNF in DM rats. 
      Furthermore, the memory-improving effects of etanercept were independent of 
      hyperglycemia. These data suggest that etanercept treatment prevents changes in 
      endothelial function, eNOS expression, and hippocampal expression of BDNF and, 
      consequently, vascular dementia in DM rats.
FAU - Utkan, Tijen
AU  - Utkan T
AD  - Director of Experimental Medical Research and Application Centre, Kocaeli 
      University, Kocaeli, Turkey. tijenutkan@hotmail.com.
FAU - Yazir, Yusufhan
AU  - Yazir Y
FAU - Karson, Ayse
AU  - Karson A
FAU - Bayramgurler, Dilek
AU  - Bayramgurler D
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Neurovasc Res
JT  - Current neurovascular research
JID - 101208439
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Brain/*drug effects/pathology
MH  - Brain-Derived Neurotrophic Factor/biosynthesis
MH  - Dementia, Vascular/*etiology
MH  - Diabetes Mellitus, Experimental/*complications
MH  - Etanercept/*pharmacology
MH  - Male
MH  - Maze Learning/drug effects
MH  - Nitric Oxide Synthase Type III/biosynthesis
MH  - Rats
MH  - Rats, Wistar
EDAT- 2015/03/12 06:00
MHDA- 2015/12/30 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/12/23 00:00 [received]
PHST- 2015/02/19 00:00 [revised]
PHST- 2015/02/19 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/12/30 06:00 [medline]
AID - CNR-EPUB-65822 [pii]
AID - 10.2174/1567202612666150311111340 [doi]
PST - ppublish
SO  - Curr Neurovasc Res. 2015;12(2):135-46. doi: 10.2174/1567202612666150311111340.